Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 29, 2024, titled "Glenmark Pharmaceuticals receives ANDA approval forAcetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)".
Press Release Apr 29 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Glenmark Pharmaceuticals Limited has received ANDA approval for Acetaminophen and Ibuprofen Tablets, which are over-the-counter medications. The approval was granted by the United States Food & Drug Administration, allowing Glenmark to distribute these tablets in the U.S. This product is bioequivalent to Advil® Dual Action with Acetaminophen Tablets, which has significant annual sales in the market. Glenmark's portfolio includes numerous products authorized for distribution in the U.S., with additional ANDAs pending approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Feb 14 2024
- Press Release Jan 31 2024
- Press Release Jan 30 2024
- Press Release Jan 25 2024
- Press Release Jan 03 2024
Later from Glenmark Pharmaceuticals
- Press Release May 17 2024
- Glenmark Pharmaceuticals Limited Press Release May 21 2024
- Press Release May 24 2024
- Glenmark Pharmaceuticals Limited Press Release Jun 12 2024
- Glenmark Pharmaceuticals Limited Press Release Jul 17 2024
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals